期刊文献+

L-精氨酸助溶菌酶复性过程动力学研究 被引量:2

Study on Kinetics of Lysozyme Refolding Facilitated by L-Arginine
在线阅读 下载PDF
导出
摘要 通过测定复性后酶活性和计算蛋白复性收率,研究了L-精氨酸助溶菌酶的最佳复性条件,利用蛋白质的复性和聚集反应竞争三态动力学模型描述了L-精氨酸助溶菌酶复性动力学,在溶菌酶浓度为100~500μg.mL-1、L-精氨酸浓度为0~1.0 mol.L-1的条件下,分析了溶菌酶浓度及L-精氨酸浓度对复性动力学常数的影响。结果表明,L-精氨酸助溶菌酶复性符合三级聚集反应动力学,L-精氨酸的主要作用是抑制蛋白聚集体的生成速率,从而达到抑制蛋白沉淀、提高复性收率的效果。 Protein refolding is an important operation in the down-stream processing of many genetically engineered proteins.L-Arginine is one of the most commonly used additives that are effective in assisting refolding of recombinant proteins from inclusion bodies.A major problem of protein refolding is aggregation of an unfolded or an intermediate state during refolding.L-Arginine may work on refolding of proteins by suppressing aggregation of proteins,thereby allowing the unfolded or intermediate state to proceed to the native state.The mechanism behind its action is still not fully understood.Using lysozyme as a model protein,the optimal refolding conditions of lysozyme refolding facilitated by L-arginine were investigated.A kinetic model based on the competition between protein folding and aggregation was employed to express the refolding process of denatured/reduced lysozyme facilitated by L-arginine.Within the range of 100~500 μg·mL-1 lysozyme,the effect of L-arginine concentration from 0 to 1.0 mol·L-1 on the refolding kinetics constants was investigated.It was found that the aggregation reaction of the L-arginine-assisted refolding could be described as a third order reaction.The primary role of the L-arginine was to suppress the aggregation reaction rate,resulting in the increasing of refolding yield.The observations suggest that L-arginine may suppress aggregation of the protein during refolding.
出处 《化学与生物工程》 CAS 2010年第10期50-54,共5页 Chemistry & Bioengineering
基金 上海市优秀青年教师科研基金资助项目(B37-0111-09-003)
关键词 蛋白质复性 溶菌酶 L-精氨酸 动力学 protein refolding lysozyme L-arginine kinetics
  • 相关文献

参考文献11

  • 1Lilie H,Sehwarz E, Rudolph R. Advances in refolding of proteins produced in E. coli[J]. Current Opinion Biotechnology, 1998, 9 (5) :497-501.
  • 2董晓燕,黄艳,孙彦.添加剂促进变性还原溶菌酶复性的作用[J].天津大学学报(自然科学与工程技术版),2004,37(7):643-646. 被引量:2
  • 3Kurganov B I. Kinetics of protein aggregation: Quantitative estimation of the chaperone-like activity in test-systems based on suppression of protein aggregation [J]. Biochemistry, 2002, 67 ( 4 ) : 409-422.
  • 4Yasuda M,Murakami Y,Sowa A,et al. Effect of additives on refolding of a denaturated protein[J]. Biotechnology Progress, 1998, 14(4) : 601-606.
  • 5Johannes B, Ira P, Ulrich B. A method for increasing the yield of properly folded recombinant fusion proteins:Single-chain immunotoxins from renaturation of bacterial inclusion bodies[J]. Analytical Biochemistry, 1992,205(2) :263-270.
  • 6Arakawa T, Tsumoto K. The effects of arginine on refolding of aggregated proteins:Not facilitate refolding, but suppress aggregation[J]. Biochemical and Biophysical Research Communications, 2003,304 ( 1 ) : 148-152.
  • 7Bajorunaite E, Sereikaite J, Bumelis V A. L-Arginine suppresses aggregation of recombinant growth hormones in refolding process from E. coli inclusion bodies[J]. Journal of Protein, 2007,26(8): 547- 555.
  • 8Goldberg M E,Rudolph R,Jaenicke R. A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme[J]. Biochemistry, 1991, 30(11) :2790- 2797.
  • 9李军,刘美杰,李勇,窦忠英.重组蛋白包涵体的研究进展[J].安徽农业科学,2008,36(31):13552-13554. 被引量:8
  • 10Reddy K R C, Lille H, Rudolph R, et al. L-Arginine increases the solubility of unfolded species of hen egg white lysozyme[J]. Protein Science, 2005,14 (4) : 929-935.

二级参考文献20

  • 1吉清,何凤田.包涵体复性的研究进展[J].国外医学(临床生物化学与检验学分册),2004,25(6):516-518. 被引量:16
  • 2万雪,王磊,宁官保.包涵体及其复性研究概况[J].畜牧兽医科技信息,2005,21(2):13-15. 被引量:5
  • 3朱希强,袁勤生.重组人EC-SOD包涵体的稀释复性及重折叠后蛋白的纯化[J].中国生物制品学杂志,2005,18(3):252-255. 被引量:3
  • 4田兴旺,张小华.分子伴侣与蛋白质折叠的研究进展[J].陕西师范大学继续教育学报,2006,23(4):115-117. 被引量:1
  • 5FISCHER L, GERARD M, CHALUT C,et al .Cloning of the 62-kilodalton component of basic transcription factor BTF2[J] .Science,1992,257:1392- 1395.
  • 6HOFFMANN F, VAN DEN HEUVEL J, ZIDEK N. Minimizing inclusion body formation during recombinant protein production in Escherichia coli at bench and pilot plant scale[J]. Enzyme Microb Technol,2304,34:235- 241.
  • 7CARRIO M M, VILLAVERDE A. Construction .and deconstruction of bacterial inclusion bodies[J] .J Biotechnol,2002,96:3- 12.
  • 8CARRIO M M, VILLAVERDE A. Construction and deconstructicn of bacterial inclusion Hndies[J]. Biotechnology,2002,9(6) : 1 - 17.
  • 9MICHELLE K, CHOWI M,ABDULLAH A,et al.The Refold database:A tool for the optimization of protein expression and refolding[J]. Nucleic Acids Research, 2006,34:207 - 212.
  • 10SHI Y,JIANG C,CHEN Q,et al. One-step on-column affinity refolding purification and functional analysis of recombinant human VDACl [J]. Biochem Biophys Res Commun,2003,303(2) :475 - 482.

共引文献8

同被引文献17

  • 1Rui Luo,Liurong Fang,Hui Jin,Yunbo Jiang,Dang Wang,Huanchun Chen,Shaobo Xiao.Antiviral activity of type I and type III interferons against porcine reproductive and respiratory syndrome virus (PRRSV)[J]. Antiviral Research . 2011 (2)
  • 2Dang Wang,Liurong Fang,Lizhi Liu,Huijuan Zhong,Quangang Chen,Rui Luo,Xiangtao Liu,Zhongming Zhang,Huanchun Chen,Shaobo Xiao.Foot-and-mouth disease virus (FMDV) leader proteinase negatively regulates the porcine interferon-λ1 pathway[J]. Molecular Immunology . 2011 (1)
  • 3Walid Abushahba,Murugabaskar Balan,Ismael Castaneda,Yao Yuan,Kenneth Reuhl,Elizabeth Raveche,Andrew Torre,Ahmed Lasfar,Sergei V. Kotenko.Antitumor activity of Type I and Type III interferons in BNL hepatoma model[J]. Cancer Immunology, Immunotherapy . 2010 (7)
  • 4Dang Wang,Liurong Fang,Fuwei Zhao,Rui Luo,Huanchun Chen,Shaobo Xiao.Molecular cloning, expression and antiviral activity of porcine interleukin-29 (poIL-29)[J]. Developmental and Comparative Immunology . 2010 (3)
  • 5Dongling Ma,Dong Jiang,Min Qing,Jessica M. Weidner,Xiaowang Qu,Haitao Guo,Jinhong Chang,Baohua Gu,Pei-Yong Shi,Timothy M. Block,Ju-Tao Guo.Antiviral effect of interferon lambda against West Nile virus[J]. Antiviral Research . 2009 (1)
  • 6Anthony Meager,Kumuthini Visvalingam,Paula Dilger,Donna Bryan,Meenu Wadhwa.Biological activity of interleukins-28 and -29: Comparison with type I interferons[J]. Cytokine . 2005 (2)
  • 7Issacs A,Lindenmann J.Virus interference: the interferon. Proc. R. Soc. Lond Ser . 1957
  • 8Sheppard P,Kindsvogel W,Xu W,et al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology . 2003
  • 9Laure Dumoutier,Amel Tounsi,Thomas Michiels,Caroline Sommereyns,Sergei V. Kotenko,Jean-Christophe Renau.Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-1: SIMILARITIES WITH TYPE I INTERFERON SIGNALING. Journal of Biological Chemistry . 2004
  • 10Ank Nina,West Hans,Bartholdy Christina,Eriksson Kristina,Thomsen Allan R,Paludan S?ren R.Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. Journal of Virology . 2006

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部